New Two-Drug attack on ALS brain inflammation begins human testing
Disease control
Not yet recruiting
This study is testing whether combining two drugs, galunisertib and nerandomilast, can slow the progression of ALS in patients who have a specific biomarker called GREM2. The drugs aim to reduce harmful inflammation and scarring in the nervous system. The trial will enroll 60 adu…
Phase: PHASE2, PHASE3 • Sponsor: Gipfel Life Sciences GmbH • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC